FDA Brief

Warning letters Food

FDA warning letter to

OptiHealth Products, Inc.

LowIssued Apr 29Posted May 12Human Foods Program

FDA warned OptiHealth Products over website claims that Super Antioxidant (OPCXtra) is a drug for diseases like diabetes and Alzheimer's.

What happened

FDA reviewed optihealthproducts.com in December 2025 and the company's Facebook page, which sends consumers to the website. FDA found claims that Super Antioxidant (OPCXtra) and bilberry/OPC antioxidants lower heart disease risk, help regulate blood sugar, and address macular degeneration, Alzheimer's, and Parkinson's. FDA says those claims make the product an unapproved new drug and a misbranded drug lacking adequate directions for use.

What FDA found

  1. FDA says website claims that Super Antioxidant (OPCXtra) can reduce disease risk or treat diseases make it a drug intended for disease use.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. FDA says the product is a new drug—not generally recognized as safe and effective for those uses and not FDA-approved—so it cannot be sold across state lines without approval.

    section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. FDA says the product is misbranded (lacking adequate directions for safe lay use) because its intended diseases are not suitable for self-diagnosis or self-treatment.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. FDA says introducing the misbranded drug into interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

FDA asks OptiHealth to notify it in writing within 15 working days of steps taken to address the violations and prevent recurrence, including documentation. If corrective actions cannot be completed in that time, the company must explain the delay and provide a completion date.

Who should pay attention

  • Dietary supplement brands making disease-related claims online
  • Marketing and e-commerce teams for supplement websites and social media
  • Sellers of antioxidant, bilberry, or OPC products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk